Stevanato Group (NYSE:STVN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Stevanato Group (NYSE:STVN) released its quarterly earnings data on Wednesday. The company reported €0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.20 by (€0.03), Briefing.com reports. Stevanato Group had a net margin of 11.99% and a return on equity of 10.52%. The business’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.18 EPS. Stevanato Group updated its FY 2026 guidance to 0.690-0.730 EPS.

Here are the key takeaways from Stevanato Group’s conference call:

• Company reported fiscal 2025 revenue growth of +9% at constant currency (7% reported), led by double‑digit growth in Biopharmaceutical & Diagnostic Solutions and a 29% increase in High‑Value Solutions, which drove ~160 bps of gross‑margin expansion; GLP‑1 sales represented ~19–20% of revenue and grew >50% year‑over‑year.
• For 2026 management guided revenue of €1.26–1.29B (€1.278–1.308B at constant currency), adjusted EBITDA €331.8–346.9M, adj. diluted EPS $0.59–0.63, and assumes an ~€80M FX headwind, gross CapEx €270–290M (net €240–260M) and breakeven to ~€20M free cash flow.
• Capacity expansions in Latina (syringes, upcoming cartridge lines) and Fishers (U.S.) are progressing—Fishers doubled validated customers and has device commercial activity targeted for late 2026/early 2027—expected to support future growth and margin improvement despite near‑term dilution.
• The engineering segment remains a headwind—Q4 revenue fell 23% and 2026 is expected to decline mid‑single to low‑double digits as lower order intake and longer sales cycles delay conversion of the pipeline despite operational optimization and higher site acceptance rates.

Stevanato Group Price Performance

Shares of STVN stock traded up €1.66 during mid-day trading on Wednesday, hitting €16.39. The company had a trading volume of 269,327 shares, compared to its average volume of 727,258. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.89 and a quick ratio of 1.30. The stock’s 50 day moving average price is €17.86 and its 200-day moving average price is €21.78. Stevanato Group has a 52-week low of €13.91 and a 52-week high of €28.00. The company has a market capitalization of $4.96 billion, a P/E ratio of 29.25, a P/E/G ratio of 1.21 and a beta of 0.57.

Analyst Ratings Changes

A number of brokerages have recently issued reports on STVN. Wall Street Zen downgraded shares of Stevanato Group from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Jefferies Financial Group set a $17.50 target price on shares of Stevanato Group in a research note on Tuesday, February 10th. Morgan Stanley began coverage on shares of Stevanato Group in a report on Monday, December 1st. They issued an “equal weight” rating and a $24.00 price target for the company. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stevanato Group in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Institutional Trading of Stevanato Group

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its stake in Stevanato Group by 10.8% during the first quarter. Royal Bank of Canada now owns 437,284 shares of the company’s stock valued at $8,930,000 after buying an additional 42,731 shares during the last quarter. Sei Investments Co. raised its holdings in shares of Stevanato Group by 16.9% during the 2nd quarter. Sei Investments Co. now owns 231,244 shares of the company’s stock worth $5,649,000 after acquiring an additional 33,419 shares in the last quarter. Raymond James Financial Inc. raised its holdings in shares of Stevanato Group by 21.2% during the 2nd quarter. Raymond James Financial Inc. now owns 567,803 shares of the company’s stock worth $13,871,000 after acquiring an additional 99,328 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Stevanato Group by 14.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 708,821 shares of the company’s stock valued at $17,316,000 after acquiring an additional 87,942 shares during the last quarter. Finally, Bamco Inc. NY grew its holdings in shares of Stevanato Group by 2.1% in the second quarter. Bamco Inc. NY now owns 1,888,050 shares of the company’s stock valued at $46,125,000 after purchasing an additional 39,528 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.